Cagrilintide CAGRI

An experimental weight-loss drug, especially promising when combined with semaglutide (as 'CagriSema'), currently in human trials. Trials show substantial weight loss, sometimes beating semaglutide alone, but it's still awaiting approval.

Also known as AM833

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial doses being finalized

Reported range Phase III trials: up to 2.4 mg once weekly

Route Subcutaneous injection

Frequency Once weekly

Duration Trial durations of up to 1-2 years

Still investigational as of early 2026 (Novo Nordisk, alone and as CagriSema with semaglutide); not an approved standalone product, so current supply is unregulated.

Where this comes from Published Phase III clinical trial data (Novo Nordisk)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.